AbbVie Inc. $ABBV Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 78,122 shares of the company’s stock after selling 6,172 shares during the quarter. Generali Asset Management SPA SGR’s holdings in AbbVie were worth $18,088,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie in the second quarter worth about $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Wells Fargo & Company raised their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Price Performance

Shares of AbbVie stock opened at $228.55 on Friday. The stock has a market capitalization of $403.94 billion, a P/E ratio of 173.14, a PEG ratio of 1.30 and a beta of 0.36. The business has a 50 day simple moving average of $226.66 and a two-hundred day simple moving average of $213.48. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the company posted $3.00 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.